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In the present study three different procedures have been compared for the determination of the 
lipophilicity of the unionized species (log Po/w) of neutral, acidic, basic, amphoteric, and zwitterionic 
drugs. Shake-flask, potentiometric and chromatographic approaches have been assayed in a set of 66 
representative compounds in different phases of advanced development. An excellent equivalence 
has been found between log Po/w values obtained by shake-flask and potentiometry, while the 
chromatographic approach is less accurate but very convenient for screening purposes when a high-
throughput is required. In the case of zwitterionic and amphoteric compounds, either for shake-flask 
and chromatographic methods, the pH has to be accurately selected in order to ensure the compound 
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The design of compounds with suitable physicochemical properties is of paramount importance 
in drug discovery, since working in the optimal space may lead to improved pharmacokinetic and 
safety profiles(Arnott and Planey, 2012; Gleeson, 2008; Leeson and Springthorpe, 2007; Manallack 
et al., 2013; Ritchie et al., 2011; Wager et al., 2010; Walker, 2014). Among the relevant characteristics 
of a compound, lipophilicity is considered a very significant parameter and, commonly, it is expressed 
as the partition coefficient between n-octanol and aqueous phase (log Po/w). Thus, lipophilicity 
determination is compulsory at early stages of the drug discovery process. Due to the wide variety of 
compound characteristics and the need of fast and reliable lipophilicity evaluation, different 
approaches for log Po/w estimation have been developed. Among them  some stand out: the reference 
shake-flask method, accurate but excessively time consuming (Andrés et al., 2015; EPA, 1996; 
OECD, 1995), the automated chromatographic techniques, faster but suitable only for unionized 
compounds in working conditions (Donovan and Pescatore, 2002; Pallicer et al., 2010), or the 
potentiometric titration approaches, which are appropriated only for substances with acid-base 
properties, requiring in addition high purity samples (Avdeef, 1993, 1992; Ràfols et al., 2012). 
Therefore, a critical evaluation of the most used log Po/w determination methods through experimental 
measurements of a wide collection of drugs belonging to different chemical groups can provide a 
useful criterion to select the most appropriate approach for each instance. 
In fact, a variety of lipophilicity values for a single drug are commonly reported in the literature 
and depend on the evaluation technique and the experimental conditions, mainly the working pH, 
used in the measurement procedure (Bio-Loom, 2017). In order to select the most appropriate 
measurement tool according to the drug chemical features, a critical study of the main causes of 
variability for the most used techniques becomes urgent. In this study, a diverse set of representative 
drugs of different chemical classes (neutral, acidic, basic, amphoteric, and zwitterionic compounds) 
have been independently examined and their log Po/w values evaluated by means of fully experimental 
procedures. The selected set of 66 acid-base APIs is representative of a previous selection of 2401 
compounds of pharmaceutical interest, as explained later in the paper. Thus, shake-flask (with LC 
analysis using UV, MS or NMR detection), as well as a chromatographic approach which combines 
the chromatographic retention with the hydrogen bond donor molecular descriptor have been 
carefully examined. Biphasic potentiometric titrations involving the drug neutralization have been 
also tested for compounds with acid-base properties. The quality of the results obtained and the 
applicability, accuracy and precision of the mentioned approaches for each class of compounds have 
been critically evaluated. It should be pointed out here that “zwitterionic class of compounds” refers 
to compounds showing a zwitterion as the predominant neutral form, whereas the “amphoteric class 
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of compounds” presents a non-charged species as the main form at pH values in between the acidic 




2.1.1 Apparatus  
pH measurements were taken with a combined Crison (Hach Lange Spain, L’Hospitalet de 
Llobregat, Spain) 5202 electrode in a Crison 2001 pH meter. The electrode system was calibrated 
with ordinary aqueous buffers of pH 4.01, 7.00 and 9.21 (25 ºC). 
Centrifugation was carried out with an Eppendorf (Hamburg, Germany) 5810R Centrifuge 
operating at 3000 rpm (radius of 16.8 cm) and 25 ºC for 15 minutes. 
Chromatographic measurements were performed with a Waters (Milford, MA, USA) Alliance 
HPLC system and a Shimadzu (Kyoto, Japan) Nexera UHPLC instrument, both with diode array 
detector, or with an Agilent (Santa Clara, CA, USA) 1200 HPLC equipped with an Agilent 6540 
UHD Accurate-Mass QTOF system which was operating in electron spray ionization (ESI) in positive 
mode. Instrument control and processing were performed by Empower1, LabSolutions and 
Masshunter 4.0, respectively. Retention data and peak areas were obtained from several columns: 
Waters XBridge BEH C18 (50 x 4.6 mm, 2.5 µm and 50 x 2.1 mm, 2.5 µm), Acquity BEH C18 (50 x 
2.1 mm, 1.7 µm), and Agilent Zorbax Eclipse XDB-C18 (50 x 4.6 mm, 1.8 µm).  
1H NMR experiments were recorded on an Agilent Mercury 400 MHz (spectrometer fitted with 
a 5 mm ID/PFG probe) with 2H lock in deuterated solvents. Acquisition and processing were done by 
VNMRj 4.2 and MestreNova, respectively.  
A T3 titrator (from Sirius Analytical Instruments Ltd., East Sussex, UK) was used for the 
potentiometric determination of pKa and log Po/w. Instrument control and data processing were done 
by Sirius T3 v1.1 software. 
 
2.1.2 Chemicals 
Acetonitrile HPLC supragradient grade and acetonitrile LiChrosolv were purchased from 
Scharlab (Sentmenat, Spain) and Merck (Billerica, MA, USA), respectively. Solutions and solvent 
mixtures were made up of water purified by the Milli-Q® plus system from Millipore (Bedford, MA, 
USA) with a resistivity of 18.2 m cm. Readymade 0.5M solutions of potassium hydroxide and 
hydrochloric acid were obtained from Merck and Sigma, respectively. 1-octanol ACS reagent and 
potassium bromide were purchased from Sigma (Saint Louis, Missouri, USA). Deuterated 
chloroform-d and methanol-d4 were obtained from Sigma Aldrich (Steinheim, Germany). 
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The chemicals used for buffer preparation were obtained from Merck (Darmstadt, Germany), 
Fluka (Steinheim, Germany), Sigma–Aldrich (Steinheim, Germany), Baker (Deventer, Netherlands), 
Riedel de Haën (Seelze, Germany) and Carlo Erba (Milano, Italy). Some of the drugs were purchased 
from Sigma-Aldrich (Steinheim, Germany), Alfa-Aesar (Ward Hill, USA), Prestwick Chemical 
(Illkirch, France) in high purity grade. Other drugs were synthesized in ESTEVE (Barcelona, Spain).  
 
2.2 Methods 
2.2.1 Shake-flask method: chromatographic quantification 
Shake-flask measurements were performed following standard procedures described in OECD 
Guidelines (OECD, 1995) or from DMSO solutions as stated by Andrés et al., 2015. The n-octanol 
and aqueous phase were mutually saturated for 24 h. The compounds were grouped according to their 
pKa values in order to select the appropriate buffers to ensure the neutral form of the solutes. 0.1N 
HCl, 0.1M NaOH, phosphoric acid, N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) or acetic 
acid solutions were used to prepare aqueous buffer systems for the pH range 2-12. In the case of the 
amphoteric or zwitterionic molecules, the log Po/w values were measured at several pH values, 
including the isoelectric point. 
The compounds were initially dissolved in DMSO at a usual concentration of 10 mM, followed 
by a dilution (generally 1:100) in aqueous buffer in the pH range 2-12. The resulting solutions were 
equilibrated with n-octanol for 1 h at 25 ºC. The phase ratio (Vw/Vo) varied from 1:1 to 100:1 
depending on the expected log Po/w value of the given compound (Andrés et al., 2015). Generally, the 
procedure 1 proposed in the cited reference was followed, with the exception of olmesartan (1b) and 
oxybutynin (3). The two phases were separated by centrifugation  and the solute concentration in the 
aqueous phase was determined by liquid chromatography with UV or MS detection.  
 
2.2.2 Shake-flask method: NMR procedure 
The NMR procedure was intended for the most hydrophilic compounds. A sample of 3-4 mg of 
the compound was dissolved in different partitions of non-deuterated aqueous phases and n-octanol, 
both saturated with each other, and the usual shake-flask equilibration was performed. Since the 
unionized form of the drug was needed, different aqueous phases were used depending on the sample: 
HCl 0.1 M (pH 1-2) was used for acidic compounds, NaOH 0.1 M (pH 12-13) for basic compounds, 
and MilliQ water in neutral compounds.  
Just after the separation of the aqueous and octanol phases, the NMR samples were prepared 
with 400 μL of aqueous or octanol phase and 300 μL of DMSO-d6. The NMR experiments were 
conducted on an Agilent Mercury 400 MHz spectrometer at 25 ºC . The 1H-NMR spectra were 
acquired using a 15º pulse with a relation delay of 15 s and 128 scans. For aqueous samples, the H2O 
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signal was suppressed using WET sequence, with 64 scans and 15 s of relaxation delay. All spectra 
were carefully baseline corrected before integration. 
log Po/w was calculated from the molar ratio of the drug in the two phases, using the integral of 
DMSO-d6 signal as a reference (Mo et al., 2010). 
 
2.2.3 Potentiometric methods  
Drug pKa values were potentiometrically determined. A solution of the compound was 
neutralized over a wide pH range (from 2.0 to 12.0), and pKa values were fitted from titration curves 
(mL of titrant vs. pH) by applying equations based on mass and charge balances. For bases and 
ampholytes, 1-2 mg of the samples were dissolved in 0.15 M KCl or in methanol/0.15 M KCl 
mixtures, pre-acidified to pH 2.0 with 0.5 M HCl, and then titrated with 0.5 M KOH solution. In the 
case of acids, the titration was performed in the opposite direction. In case of poorly soluble drugs, 
pKa values were measured at several methanol/water compositions and aqueous pKa was obtained 
from the Yasuda-Shedlovsky model (Avdeef et al, 1993). 
log Po/w values were obtained from the difference between the aqueous pKa of the species and 
the apparent pKa determined from dual-phase titrations (n-octanol/KCl 0.15 M) (Avdeef, 1993, 
1992). Typically, 1-2 mg of the samples was titrated as in aqueous pKa, in presence of various 
amounts of the partitioning solvent, water-saturated n-octanol. The phase ratio applied was varied 
depending on the expected log Po/w value of the compound. log Po/w values were estimated and refined 
by a weighted non-linear least-squares, where the aqueous pKa values were used as unrefined 
contributions. log Po/w values determined from different phase volume ratios were averaged and the 
ion-pair partitioning of charged species was also characterized. 
 
2.2.4 Chromatographic methods 
Retention data were obtained working with mobile phases at different pH values containing 
aqueous buffers with usually 40 or 50% (v/v) of acetonitrile. The compounds were grouped according 
to their pKa values in order to select the appropriate buffers to ensure the neutral form of the solutes 
(generally, pH≈ pKa -2 for acids and pH≈ pKa +2 for bases). Trifluoroacetic, acetic, phosphoric, or 
citric acids or ammonium bicarbonate buffer (each at 0.010 or 0.1M, treated with various amounts of 
0.1M NaOH or ammonium) were used as the aqueous buffer phase for the pH range 2-11. For pH 12 
measurements, 10 mM pyrrolidine served as the aqueous phase. In case of amphoteric or zwitterionic 
molecules, log Po/w was measured at pH values corresponding to the isoelectric point. When pKa 
values were too close to achieve the isoelectric point, a retention vs. pH profile was obtained in the 
pH range between 3 and 12 using 10 mM solutions of citric acid or ammonium hydrogencarbonate. 
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The drugs were dissolved in methanol, potassium bromide was used as dead time marker and a UV 
detector was employed. 
In order to properly determine lipophilicity from chromatographic data it is needed to 
complement the measured retention with the hydrogen bond donor ability of the specific compound. 
In the present study the A molecular descriptor proposed by Abraham (Abraham, 1993) was selected 
as solute hydrogen bond acidity (Pallicer et al., 2013, 2010). A values for the selected compounds 
were calculated from the Absolv prediction module (ACD/Labs, 2017). 
 
2.3 Computational software 
A list of 122 2D-descriptors were calculated for the whole 2401 compounds with hydrogens 
added to the structure, using either Discovery Studio 2016 (Dassault Systèmes, 2017) or MOE 
(Molecular Operating Environment, 2017) software. Different classes of descriptors were used: 
topological such as the Balaban, Wiener, Zagreb, Kappa Shape and connectivity indices; adjacency 
and distance matrix descriptors such as the diameter or largest value in the distance matrix; graph-
theoretical information content descriptors; molecular property, atom and bound counts, such as the 
number of hydrogen bond donors and acceptors and the vertex adjacency information; partial charge 
descriptors and finally physical properties such as atomic polarizabilities and surface area and volume 
related descriptors (listed in appendix 1). Only 2D-descriptors were selected in order to avoid any 
conformational ambiguity, and the finally chosen ones are well known for their contribution in 
determining quantitative structure activity relationships (Todeschini and Consonni, 2000). 
Principal component analysis (PCA) and the calculation of the diversity metrics were done with 
Discovery Studio 2016.  
 
3. Results and discussion 
 
3.1 Representativeness assessment of the studied set of drugs 
Firstly, a working set of 66 Active Pharmaceutical Ingredients (APIs) was a priori selected 
taking into account, mainly, the structural diversity. In order to assess the adequacy of the selected 
set of APIs, in relation to its representativeness versus the whole set of advanced compounds (phase 
III, launched or withdrawn), a search in the Thomson Reuters Integrity database (Clarivate Analytics, 
2017) was performed (dietary supplements, polymers, mixtures and drug delivery systems, as well as 
inorganic complexes were excluded). The resulting 2679 unique structures were then further filtered 
by their molecular weight, requiring a value equal or lower than 600 Da, further by their number of 
rotable single bonds, accepting 15 or less, and by the fraction of rotatable single bonds divided by the 
number of bonds between heavy atoms, having to be equal or less than 0.5. The purpose of this 
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filtering stage was to concentrate on typical small molecule drugs, ending up with a set of 2401 unique 
structures. The 66 APIs selected a priori as working set were among these large group of drugs. To 
characterize the whole set of 2401 compounds a PCA was performed on the 122 calculated descriptors 
described above, with the first three principal components accounting for the 67.1% of the total 
variance (Fig. 1). Then the representativeness of our set of 66 APIs in the total space covered by the 
2401 compounds was evaluated. The diversity metrics are shown in Table 1, which compiles 
minimum and average distances among the 66 APIs and the whole set of 2401 compounds using two 
alternatives for distance calculations: the properly scaled 122 descriptors and the ECFP_6 fingerprints 
(Rogers and Hahn, 2010). Table 1 also shows the cell coverage of both groups of compounds, where 
cells have been defined by the first three principal components, using two different bin sizes. The 
representativeness of the set of the 66 APIs can be assessed by looking at the minimum distance 
among its compounds, which increases by ten in comparison to the minimum distance that can be 
found among the compounds in the whole set of 2401 substances, and this either measuring the 
distance using real-value descriptors or ECFP_6 fingerprints. Additionally, the average cell density 
of the 66APIs decreases to almost one when partitioning the coordinate space defined by the first 
three PCAs using a bin size of two. This indicates low redundancies in terms of the chemical 
properties covered by the descriptors. For bigger bin sizes, as shown in the table for a bin size of five, 
the cell density for the selected compounds is still low and the density reduction when compared to 
the whole set is of one order of magnitude. In summary, it can be concluded that the selected set of 
66APIs preserves the chemical diversity of the whole set but reducing redundancies. 
 
3.2 Prior remarks: techniques, log Po/w ranges, and ionization of compounds 
Recommending a unique and very reliable procedure for log Po/w determination of any drug or 
drug candidate is, at the moment, not realistic. This is because of the wide variety of chemicals 
involved in therapeutic treatments and also the specific limitations of each experimental approach. 
However, some remarks should be considered before discussion of results. Thus,   
a) The reference method for lipophilicity estimation is the shake-flask, since it deals with the direct 
measurement of n-octanol/aqueous buffer partition. However, according to general guidelines, the 
experimental log Po/w values to be determined should be in principle between -2 and 4 
(occasionally up to 5) (OECD, 1995).  
b) To get reliable log Po/w values for acidic, basic, amphoteric, and zwitterionic compounds, when 
using either shake flask or chromatographic procedures, it is compulsory to make the 
measurements when the compound of interest is entirely in its neutral form, avoiding partially 
ionized species. In the shake-flask method, as long as pKa values are accurately determined in 
water, it is easy to select an aqueous buffer with a suitable pH. However, some cautions should be 
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taken when the chromatographic approach is selected, because the hydroorganic mobile phase 
contains an important fraction of organic modifier that might significantly change the compound 
pKa value, modifying in this way the molar fraction of the neutral species. Thus, acids increase 
their pKa values with the content of organic modifier, whereas bases show the reversed trend 
(Subirats et al., 2007). This variation on pKa values not only affects analytes, but also buffering 
species, leading to an increase or decrease of mobile phase pH values depending on the nature of 
the buffers and the content of organic modifier. This might be especially relevant in the case of 
amphoteric compounds. For instance, in aqueous solution when the acidic and the basic pKa are 
close, the molar fraction of the neutral form might be far from 1. Nevertheless, the organic modifier 
content of the mobile phase is responsible for significant pH and pKa variations, which can change 
the drug species present in working solution. As a general rule, it might be pointed out that 
increasing the acetonitrile content in the mixed solvent has a clear advantage for amphoteric 
compounds since the mole fraction of neutral species is generally raised. On the contrary, for 
zwitterions the mole fraction of neutral species decreases with the content of the organic solvent. 
Figure 2 shows the cases of tapentadol, enalapril, and telmisartan as representative examples of 
the above mentioned. The first drug is an amphoteric compound with a mole fraction of neutral 
species of about 60% at pH 10 in water, but with the addition of acetonitrile this mole fraction 
increases above 95% in a mobile phase containing a 50% of organic modifier, because of both the 
pKa decrease of the basic functional group (from 9.44 to 8.77) and the pKa increase of the acidic 
one (from 10.47 to 12.28), broadening the difference between the pKa values of basic and acidic 
moieties from 1.0 in water to 3.5 in the hydroorganic mixture. Contrarily, enalapril is a zwitterionic 
compound which in the presence of organic solvent displays a lower separation between acidic 
and basic pKa values (from 3.03 to 4.04 and from 5.35 to 4.43, respectively), shortening the pKa 
separation from 2.3 in water to 0.4 in the mixed solvent. Finally, telmisartan is a nice and complex 
example of a zwitterionic drug in aqueous solution that becomes, mainly, an amphoteric compound 
with the addition of acetonitrile. In water the pKa of the acidic moiety (4.39) is lower than that of 
the basic one (6.02), but this is no longer the case at 50% of acetonitrile (5.78 and 5.00). However, 
either in water or in the hydroorganic solvent, the molar fraction is significantly lower than 1.  
c) The chromatographic method used in this work is a simplified approach (Pallicer et al., 2013) of 
the more complex one previously proposed (Pallicer et al., 2010). Both procedures take into 
account the experimental chromatographic retention and some molecular descriptors that were 
shown to be necessary for the proper calculation of log Po/w. The solely retention measurement is 
unable to correctly describe the drug lipophilicity, since log Po/w quantity is independent of the 
hydrogen bond acidity whereas the chromatographic retention on C18 columns strongly depends 
on it (Pallicer et al., 2013; Valko et al., 2001). The used simplified approach involves only one 
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descriptor, the Abraham’s A parameter, which can be easily estimated from the compound 
structure using either a commercial software package (ACD/Labs) or the open access UFZ-LSER 
Database (Ulrich et al., 2017). It was proved that this method is able to properly estimate log Po/w 
values from -1 to 7 (Pallicer et al., 2012), broadening in two orders of magnitude the lipophilicity 
range proposed in previous guidelines (OECD, 2004). 
d) Two potentiometric titrations of the drug, with and without n-octanol, allow the log Po/w 
determination of compounds with acid-base properties. In these instances, the solubility of both 
acidic and basic species is the limiting feature to get reliable results. Regarding to the limits of 
applicability, a very good agreement was reported between log Po/w values obtained by shake-flask 
and potentiometry in the range between -1.8 and 5.8 for 23 structurally diverse compounds 
(Takács-Novák and Avdeef, 1996). 
 
3.3 Comparison between shake-flask, potentiometric and chromatographic methods 
The first challenge to solve was the adoption of an equivalence criterion between log Po/w values 
obtained from different techniques. There is a well-known experimental variability in log Po/w 
measurements, even following the same procedure, which led the Association of Official Analytical 
Chemists (AOAC) to admit differences of 0.3 units between log Po/w values measured from replicates 
using the shaking flask reference method (EPA, 1996; OECD, 1995). A tolerance limit of 0.6 was 
proposed for the chromatographic method used in this work (Pallicer et al., 2010), bearing in mind 
that different columns and mobile phases can be employed. This equivalence criterion is consistent 
with the variety of values shown for most compounds in the literature (Leo et al., 1995) and in the 
Bio-Loom database (Bio-Loom, 2017). Therefore, in the present work all the results included in an 
interval of 0.6 units between the higher and the lower obtained log Po/w values are considered as 
equivalent.  
Table 2 shows the measured lipophilicity values for the representative set of 66 drugs belonging 
to five chemical classes, which were measured by the three methods previously mentioned: shake 
flask, chromatography, and potentiometry. Potentiometrically determined acidity constants, together 
with experimental literature (when available) and calculated log Po/w values (ClogP), are also listed 
in this table. ClogP (Bio-Loom, 2017) was the selected software because of its superior performance 
in the case of highly diverse compounds (Pallicer et al., 2014). 
For some of the studied compounds not all the three experimental procedures could be 
successfully applied. The potentiometric procedure failed for those compounds with log Po/w values 
higher than 5.5 (clofazimine and rimonabant), and in the case of clopamide due to solubility issues. 
In case of very poorly soluble compounds the presence of a precipitate might not be visually evident 
for very low octanol-water volume ratios, since the stirred solutions are turbid. Diltiazem suffers from 
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degradation in alcohol-water mixtures (Andrisano et al., 2001), leading to non-reliable lipophilicity 
values in a shake-flask procedure involving long times in solution. A similar behavior was observed 
for clopidogrel. In relation to the chromatographic approach, topiramate and amantadine were not 
detected by UV, and isoproterenol was not sufficiently retained in the column. 
As presented in Figure 3 and considering shake-flask as the reference method for log Po/w 
determination, excellent correlations were observed with potentiometry independently of the acid-
base properties of the compounds. Only four compounds showed differences higher than 0.6 log Po/w 
units, the basic oxybutynin and prenylamine, and the zwitterionic levodopa and telmisartan. This 
figure also shows a good correlation between shake-flask and chromatography, but with a lower 
degree of equivalency between log Po/w values.  
Table 3 shows the percentage of compounds with differences between the lowest and the 
highest log Po/w values obtained by different techniques not higher than 0.6 units. Equivalent results 
for the three approaches were obtained for 60% of the substances, being especially remarkable the 
high equivalency in the case of acids. As expected, the results obtained by shake-flask excellently 
matched those retrieved by potentiometry (Figure 3A), and a lower degree of equivalency was found 
when compared with chromatography (Figure 3B). However, it should be pointed out that several 
compounds, which were considered as non-equivalent, were in fact only slightly beyond the 0.6 limit. 
 
3.4 Comparison with literature values 
With the exception of levodopa, there is a good agreement between literature log Po/w values 
and those measured in this work by shake-flask, potentiometry, and chromatography. Only 
experimental lipophilicity values tagged with the “highest quality” in Bio-Loom database (obtained 
from different techniques, such as shake-flask, potentiometry, liquid chromatography, micellar or 
microemulsion electrokinetic chromatography, thin layer chromatography…) were used in this study 
for comparison. It must be pointed out that in some cases literature log Po/w values were determined 
for ionized species and then these values were somehow corrected for ionization. As shown in Table 
4, lipophilicity data measured from shake-flask and potentiometric methods nicely agree with 
literature values, presenting relatively high determination coefficients (R2), and intercepts and slopes 
close to 0 and 1, respectively. Correlation is slightly worse for the chromatographic method.  
Figure 4 is a comprehensive plot of the correlations above mentioned, showing the different 
nature of the compounds studied (acids, bases, neutral, amphoteric, and zwitterionic) and the 
experimental procedures followed (shake-flask, pontentiometry, and chromatography). The main 
outlier is levodopa, for which both the shake-flask and chromatographic methods gave the same value 
(1.58 and 1.57, respectively), while potentiometry provided one log Po/w unit lower (0.50). These 
values were much higher than those selected by Bio-Loom database and calculated by the prediction 
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software ClogP (-2.74 and -2.84, respectively). In fact, the database reports several lipophilicity 
values for levodopa considered of lower quality in the range between -1.72 and -4.70. Labetalol, also 
a zwitterionic compound, shows very similar log Po/w values measured from the three different 
procedures, but about 1.5 units lower than the literature highest quality value (although other reported 
values in the same Bio-Loom database are comprised between 0.66 and 1.24). However, Avdeef 
reports a value of 1.33 for this compound (Avdeef, 2012), which would be equivalent to those 
obtained in this work by shake-flask, potentiometry, and chromatography. A similar feature is 
observed in the case of the basic compound ranitidine, with additional literature values of 0.27 (Bio-
Loom, 2017) or 0.45 (Avdeef, 2012), much closer to those obtained by the three different techniques 
compared in this study.  
Concerning the highly lipophilic substances rimonabant and clofazimine, there is again a good 
match between chromatographic and shake flask procedures (such a high lipophilicity is beyond the 
reach of actual potentiometric techniques), but they are lower than the reported literature log Po/w. 
The value of 7.48 for clofazimine is very similar to the calculated ClogP value, but we should bear in 
mind that experimental determination of highly lipophilic compounds may lead to significant levels 
of uncertainty. In the case of rimonabant, a log Po/w value of 5.8 from chromatographic measurements 
is also reported in the Bio-Loom database, showing in this case a better agreement for both the 
chromatographic (6.00) and the shake-flask (5.57) methods assayed in this work.  
 
3.5 Chromatographic considerations for amphoteric and zwitterionic compounds  
Regarding the chromatographic approach for amphoteric and zwitterionic compounds, it must 
be pointed out that direct measurement of retention at a particular pH in the vicinity of isoelectric 
point might not be sufficient for the determination of a proper log Po/w value, especially in the case 
of compounds with close acidic and basic pKa values. As previously commented (Figure 2), for 
zwitterionic compounds the pKa difference between acidic and basic groups shortens with the addition 
of acetonitrile and thus the maximum recorded retention might not correspond to that of the fully 
unionized species (molar fraction lower than 1). Thus, it is convenient to measure retention in relative 
wide range of pH values (measured in the mobile phase) and fit the data to the following equation in 





(pH p ) (2pH p p )
HXH X X


















k   are the fitted retention factors of 
the positively and negatively charged species, respectively, and pKa1 and pKa2 are the fitted acidity 
constants. Examples of application of this approach are presented in Figure 5 for tapentadol and 
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rosiglitazone. In mobile phases containing 50% of acetonitrile, the pKa values of tapentadol are 
separated enough to have the compound at about pH 10.5 in its nearly fully neutral form. Thus, the 
fitted kHX value (3.40) is very close to that measured at pH 10.49 (3.32). In contrast, the fitted kHX of 
rosiglitazone (3.52) is significantly higher than the maximum retention directly achieved from a 
single chromatogram (2.97 and 2.96 at pH 6.22 and 6.59, respectively). Clearly, the elaboration of a 
retention vs. pH profile could be excessively time consuming for a chromatographic approach for 




The present study confirms that shake-flask with LC-UV, LC-MS or NMR detection is the most 
universal method for determination of partition coefficients, since it is relatively simple and adequate 
for both neutral and ionizable compounds. For the set of 66 compound studied in this work it gives 
an excellent correlation with literature data, but its major drawbacks are that it is time consuming 
(phase equilibration + quantification procedure) and in the case of highly lipophilic or sparingly 
soluble compounds highly sensitive quantification systems are required. Potentiometric titrations are 
fully automatizable and significantly reduce the time required for measurement, but are only suitable 
for acidic or basic compounds, require samples of a high purity and might not be adequate for highly 
lipophilic substances due to solubility issues. Chromatographic measurements can be used for both 
neutral and ionizable compounds, are fully automatizable and time saving, but mobile phase 
compositions must be carefully selected in order to ensure the compound in its unionized species 
(mobile phase pH and analyte pKa depend on the content of organic modifier).  
The equivalency between log Po/w values obtained by shake-flask and potentiometry is excellent 
in the whole studied range (between -1.1 and 5.6). These results, obtained with a broader set of 
representative compounds, are consistent with a previous study (Takács-Novák and Avdeef, 1996), 
suggesting that the upper limit of log Po/w 4 recommended in the shake-flask guidelines (OECD, 
1995) can be shifted up provided that and adequate ratio octanol/water is used and the quantification 
system is sensitive enough. 
Generally, good correlations are obtained when comparing the shake-flask and the 
chromatographic methods. This time saving approach, although it might be less accurate, is 
particularly convenient for those highly lipophilic compounds beyond the limits of shake-flask and 
potentiometry and for solutes presenting stability issues in time consuming determinations.  
Among all the compound classes studied, the amphoteric and zwitterionic compounds are the 
more complex. The determination of their lipophilicity is not straightforward, mainly because the pH 
at which the neutral species can be found might be difficult to identify. This is especially the case 
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when using chromatographic methods, where the variations on analyte pKa and mobile phase pH with 
the addition of organic solvent should be taken into consideration, and consequently each case must 
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Table 1. Diversity metrics from the PCA study using the calculated 122 descriptors. 
 APIs Average / Minimum distance
Occupied cells / Average cell density
Bin-size 2 Bin-size 5 
122 descriptors 2401 1.313 / 0.036 766 / 3.13 130 / 18.47 
 66 1.350 / 0.304 59 / 1.12 31 / 2.13 
Fingerprint 2401 0.909 / 0.039   





Table 2. pKa and log Po/w values of the studied drugs.  
  log Po/w   
Compound pKa valuesa Shake-flaskb Potent.a Chrom. Bio-Loomi Lit.j ClogP 
Acidic        
Acetaminophen 9.39(A) 0.40 (1.0) 0.49 0.57 0.51 0.34 0.49 
Atorvastatin 4.04(A)d 4.00 (2.0) 4.08d 4.50g 4.18 - 4.46 
Celecoxib 9.55(A) 3.90 (2.0) 3.91 4.20g - - 4.57 
Flufenamic 4.16(A)d 4.64 (2.0) 5.19d 4.83g 5.25 5.56 5.38 
Glimepiride 5.38(A)d 4.02 (2.0) 3.97d 4.30g - - 3.96 
Hydrochlorothiazide 8.72(A), 9.96(A) 0.00 (2.0) -0.04 0.74 -0.07 -0.03 -0.37 
Indomethacin 3.98(A)d 3.89 (2.0) 4.10d 3.83g 4.27 3.51 4.18 
Ketorolac 3.50(A)d 2.71 (2.0) 2.62d 2.60 1.68 1.88 1.62 
Naproxen 4.28(A)d 3.12 (2.0) 3.24d 2.93g 3.34 3.24 2.82 
R-Flurbiprofen 4.35(A)d 3.97 (2.0) 3.84d 3.73g 3.86 3.99 3.75 
Rosuvastatin 4.44(A)d 2.46 (2.0) 2.52d 2.58g - - 1.90 
Topiramate 8.55(A) 0.47 (1.0) 0.58 - - - 0.04 
Valsartan 3.84(A)d, 4.69(A)d 3.37 (2.0) 3.52d 3.20g 3.9 3.90 4.86 
Warfarin 5.01(A)c 3.19 (2.0) 3.28 3.41g 2.70 3.54 2.90 
Zonisamide 9.49(A) 0.50 (2.0) 0.77 1.01 - - -0.36 
Basic        
Amantadine 10.62(B) 2.32 (12.5) 2.52 - 2.44 - 2.00 
Atenolol 9.40(B)d 0.13 (12.0) 0.06d 0.22g 0.16 0.22 -0.11 
Chlorpromazine 9.25(B)d 5.40 (12.0) 5.27d 5.44g 5.35 5.40 5.50 
Clofazimine 8.38(B) 6.30 (12.0) - 5.93g 7.48 - 7.55 
Clopidogrel 4.99(B)d - 4.52d 4.84g - - 4.21 
Diltiazem 7.79(B)d - 2.84d 3.02g 2.8 2.89 3.65 
Duloxetine 9.81(B)d 4.07 (12.0) 4.54d 4.04g - 3.76k 4.26 
Famotidine 6.67(B) -0.75 (11.5) -0.36 0.65 -0.8 -0.81 -0.86 
Fluoxetine 9.89(B)d 4.21 (12.0) 4.42d 4.26g 4.5 4.50 4.57 
Loratadine 4.86(B)d 4.45 (12.0) 4.88d 4.30g 4.4 - 5.05 
Miconazole 5.99(B)d 5.58 (12.0) 5.38d 5.68g 5.34 4.89 5.81 
Milnacipran 9.55(B)d 1.37 (12.0) 1.72d 2.57g 2.03 - 1.91 
Mirtazapine 3.77(B), 7.65(B) 3.06 (12.0) 3.28 2.78 3.48 - 3.07 
Oxybutynin 7.72(B) 5.29 (10.5) 4.59 5.34 - - 4.69 
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Prenylamine 9.31(B) 3.82 (12.0) 5.07 5.94 - - 5.80 
Quetiapine 3.57(B)o, 6.97(B)o 2.91 (12.0) 3.13d 2.50g 2.84 - 2.99 
Ranitidine 2.18(B)d, 8.38(B)d -0.24 (11.5) 0.26d 0.06g 1.03 0.45 0.85 
Rimonabant 2.80 (B)d 5.57 (12.0) - 6.00g 6.7 - 6.12 
Sertraline 9.31(B)d 4.73 (12.0) 5.17d 5.38g - 4.9l 5.35 
Terfenadine 9.27(B) 4.96 (12.0) 4.47 6.08 5.69 5.52 6.07 
Tramadol 9.50(B)d 2.64 (11.5) 2.70d 3.28g 2.63 2.31 3.10 
Trimipramine 9.21(B) 4.55 (12.0) 4.77 5.87 - - 5.44 
Venlafaxine 9.59(B)d 2.81 (12.0) 3.05d 3.74g 3.0 - 3.27 
Verapamil 8.81(B) 3.63 (11.5) 4.07 4.43 3.97 4.33 4.27 
Vildagliptin 7.52(B)d -0.57 (11.5) -0.16d -0.08g - - 0.97 
Neutral        
Carbamazepine - 1.40 (7.0) - 1.90g 2.19 2.45 2.24 
Lacosamide - 0.21 (7.0) - -0.14 - - 0.39 
Levetiracetam - -0.14 (2.0) - 0.48g - - -0.34 
Oxcarbazepine - 1.17 (7.0) - 1.08 - - 1.21 
Sulfinpyrazone - 1.35 (7.0) - 2.26 2.30 3.93 2.43 
Taranabant - 4.94 (2.0) - 5.69 - 5.2m 5.79 
Amphoteric        
Clopamide 2.72(B), 8.95(A) 1.00 (5.2) - 1.33 - - 2.37 
Folic acid 2.30(B), 3.79(A), 4.67(A), 7.97(B) - 0.10 - - - -1.70 
Haloperidol 8.54(B)f, 10.98(A)f 3.52f 3.61f 3.66g 3.82 3.67 3.85 
Isoniazid 3.53(B)e, 11.14(A)e -0.65e -0.85e -0.95h -0.70 - -0.67 
Isoproterenol 8.66(B), 9.95(A) - -0.62 - - - 0.15 
Mebendazole 3.53(B)f, 9.88(A)f 3.09f 2.92f 1.82 2.83 3.28 3.08 
Nalidixic acid 6.00(A)f 1.36f 1.48f 1.98 1.59 1.41 1.02 
Omeprazole 4.25(B)d, 8.64(A)d 2.23 2.14d 1.40g 2.23 5.42 2.57 
Pantoprazole 3.84(B), 8.22(A)f 2.07f 1.84f 1.34 - - 2.11 
Pioglitazone 5.56(B), 6.52(A) - 4.03 3.22 - 3.31n 3.53 
Rosiglitazone 6.26(B)d, 6.67(A)d - 3.10d 3.29 - 2.78n 3.02 
Sulfamethoxazole 1.67(B), 5.65(A)f 0.86f 0.90f 1.44g 0.89 - 0.56 
Tapentadol 9.44(B), 10.47(A) - 2.88 3.37 - - 3.15 
Zwitterionic        
Benazepril 3.35(A)f, 5.43(B)f 1.24f 1.38f 2.05 - - 1.82 
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Ciprofloxacin 6.20(A)f, 8.56(B)f -1.13f -1.15f -1.20 -1.08 -1.08 -0.47 
Enalapril 3.03(A), 5.35(B) -0.04 (4.2) -0.09 0.14 -0.07 0.16 0.67 
Labetalol 7.41(A)f, 9.37(B)f 1.45f 1.37f 1.74 3.09 1.33 2.50 
Levodopa 2.77(A), 8.49(B), 10.29(A) 1.58 (5.6) 0.50 1.57 -2.74 - -2.82 
Ramipril 3.53(A), 5.79(B) 1.06 (4.7) 0.72 0.77 1.04 - 1.54 
Telmisartan 3.01(B)f, 4.39(A)f, 6.02(B)f 4.18f 3.54f 4.03 - 7.46 7.29 
a Potentiometrically determined at a ionic strength of 0.15 M 
b pH of the aqueous phase in brackets; determined at a ionic strength of 0.10 M 
c From ref. (Völgyi et al., 2007). 
d From ref. (Pallicer et al., 2012). 
e From ref. (Ràfols et al., 2012). 
f From ref. (Ràfols et al., 2017). 
g Calculated from ref. (Pallicer et al., 2013). 
h Calculated from ref. (Pallicer et al., 2010). 
i Compiled experimental log Po/w values with the “highest quality” tag (Bio-Loom, 2017), obtained from different techniques (shake-flask, 
potentiometry, chromatography…). 
j Compiled experimental log Po/w values from ref. (Avdeef, 2012). 
k From ref. (Martin et al., 2008). 
l From ref. (Avdeef and Sun, 2011). 
m From ref. (Liu et al., 2007). 
n From ref. (Giaginis et al., 2007). 




Table 3. Percentage of compounds with equivalent log Po/w obtained by different techniques (total 
number of compounds in each category in brackets). 
 SF - P - C SF - P SF - C P - C 
Overall 60% (48) 92% (50) 68% (57) 74% (53) 
   Acidic 93% (14) 100% (15) 93% (14) 93% (14) 
   Basic 45% (20) 90% (21) 59% (22) 64% (22) 
   Neutral - - 50% (6) - 
   Amphoteric 43% (7) 100% (7) 50% (8) 70% (10) 
   Zwitterionic 57% (7) 71% (7) 86% (7) 71% (7) 




Table 4. Correlations between log Po/w values obtained from literature and measured in the present 
work (excluding levodopa). Standard errors of the fitted parameters in brackets. 
 Shake-flask Potentiometry Chromatography
Intercept -0.02 (0.13) 0.01 (0.13) 0.26 (0.16)
Slope 0.92 (0.04) 0.96 (0.04) 0.89 (0.05)
R2 0.940 0.943 0.904







Figure 1. Representativeness assessment of the studied set of drugs by PCA. Large red symbols show 






Figure 2. Mole fraction of the different species of tapentadol, enalapril and telmisartan in aqueous 
solution and in a mobile phase containing 50% in volume of acetonitrile. pKa values in hydroorganic 





Figure 3. Correlations between potentiometric (A) and chromatographic (B) vs. shake flask log Po/w 
values. The statistics of linear regressions (slope, intercept, determination coefficient and number of 
observations) are presented in the figure, together with a solid straight line of null intercept and 
unitary slope, representing a total match between sets of log Po/w values, and dashed lines in order to 






Figure 4. Correlations between log Po/w values measured in this work and found in the literature (Bio-
Loom), depending on the technique employed and the acid-base properties of the drugs. Legend: 
(squares) shake-flask, (circles) potentiometry, (diamonds) chromatography; (filled symbols) acids, 
(empty) bases, (crossed) neutral, (upper-half filled) amphoteric, (lower-half filled) zwitterionic. A 
straight line of unitary slope and null intercept is also shown in the figure. 
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